Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.
EP. 1: Emerging Trends and Rising Prevalence of mCSPC
October 25th 2024Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.